tbuckley/cabot-search huggingface dataset:
Medical Diagnosis. A Manual of Clinical Methods for Practitioners and Students. Fifth Edition.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A patient's eye view of quality
Journal: BMJ (1999)

he story would make a marvellous soap opera.The research, into immunological genetics and published in Cell, is complex, made worse by the inadequate English of Teresa Imanishi-Kari, the Brazilian-Japanese research worker.Accused of fraud, she is defended by her charismatic but hubristic boss, the Nobel laureate David Baltimore, who takes on a congressional committee.The whistleblower, Margot O'Toole, a young Irish radical, loses her job, house, and career-but receives international honours and publicity for her courage.After 10 years and seven inquiries, reviews, and the final, successful, appeal, the US immunological
HBeAg seroconversion during treatment with peginterferon-alfa2a (PEG-IFN) is preceded by selection of hepatitis B virus basal core promoter and pre-core variants which are associated with decreased HBV replication
Authors: Maria Pfefferkorn, Carolin Hahn, Karen Rother, Danilo Deichsel, Cynthia Wat, Thomas Berg, Florian van Bömmel
Journal: Journal of Hepatology (2020)
Worcester Infirmary
Journal: BMJ (1858)

doses of opium, the hiccough became manifestly less, and gra- dually ceased.There was much less perspiration during the day.The pulse became regular, with more power.April 11th.He passed a good night; there was no hiccough, and very little perspiration.There was a little redness re- mair.ing about the stump, but no pain.He took no medicine, with the exception of one or two grains of opium at night.The stimulants were continued.April 15th.The leg and foot were still somewhat cedema- tous; the stump was nearly healed.He had had no return of hiccough, and slept without opium.The stimulants had been reduced to ten ounces of wine, and fifteen ounces of brandy.April 28th.He was progressing favourably, and had been able to get about the ward for some days, with the aid of crutches.The stimulants were reduced to four ounces of brandy, six ounces of wine, and one pint of bitter ale.May 20th.The stimulants had been gradually reduced to
Treatment of hypertension in the elderly
Authors: H. I. Tjoa
Journal: JAMA (1990)

Hypertension, both combined diastolic plus systolic and isolated systolic, is common in the elderly. Elderly hypertensive patients pose a number of diagnostic dilemmas, including pseudohypertension, postural and postprandial decreases in blood pressure, and the potential for renovascular hypertension. Data from large clinical trials have documented protection from cardiovascular complications by antihypertensive therapy for elderly people with combined systolic and diastolic hypertension. However, no data are available concerning the value of therapy for those with isolated systolic hypertension. Until such data become available from the Systolic Hypertension in the Elderly Program in 1991, cautious reduction of elevated systolic blood pressure levels is recommended. The fragile physiologic characteristics of the elderly demand caution and gentleness in the use of any therapy to lower blood pressure. Nondrug therapies are safe and may be effective. A variety of drugs are available and can be used to gradually reduce blood pressure to presumably safer levels. (<i>JAMA</i>. 1990;264:1015-1018)
Seventh Annual Report of Diphtheria Mortality in the Large Cities of the United States.
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Alveolar Hydatid Disease of Liver: Rationale and Techniques of Surgical Treatment
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Continuing Medical Education
Authors: J. K. Weston
Journal: JAMA (1979)

<h3>To the Editor.—</h3> Relative to the correspondence exchange between Dr Derbyshire and Drs Stross and Harland (240:2248, 1978), I would comment in this medically important and most misunderstood area. First, I strongly concur with the foregoing physicians that continuing medical education (CME) methods and evaluation must be improved by any of the numerous interested and active organizations and persons involved. Like many others, I have realized this and have advocated it since the 1930s. Second, Stross and Harland rightfully strike the nub of the matter. They note: "increasing participation in itself is not important unless that participation is in meaningful CME activities. At present, we think CME is still in an embryonic stage of development and that the majority of programs do not fulfill the educational needs of the audience and are poorly evaluated." I am in full agreement with them here. Third, to the degree that the aforementioned be
Diagnosis, Differential Diagnosis and Treatment of Diseases of the Eye.
Journal: JAMA (1894)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Olaparib Targets Some Advanced Prostate Cancers
Journal: Cancer Discovery (2015)

In the phase II TOPARP-A clinical trial, patients with metastatic castrate-resistant prostate cancer who were treated with the PARP inhibitor olaparib lived nearly three times longer without their cancer worsening if their tumors had mutations in at least one of 12 DNA repair genes. However, physicians say that a larger trial is needed to confirm olaparib's effectiveness against the disease before they start routinely sequencing tumors and prescribing the drug.
Structured Abstracts
Authors: George A. Diamond
Journal: Annals of Internal Medicine (1990)

Letters1 November 1990Structured AbstractsGeorge A. Diamond, MDGeorge A. Diamond, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-113-9-722 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editors:Recently, a manuscript editor of theAnnals of Internal Medicineasked me to compose a "structured abstract" for a review article I wrote. As a courtesy, she referred me to another review extolling the virtues of the form (1). I was surprised to see that this article did not itself contain a structured abstract. Does this meanAnnalsadvocates using this structure onlyin the abstract?...Reference1. HaynesMulrowHuthAltmanGardner RCEDM. More informative abstracts revisited. Ann Intern Med. 1990;113:69-76. LinkGoogle Scholar1. HaynesMulrowHuthAltmanGardner BCEDM. More informative abstracts revisited. Ann Intern Med. 1990;113:69-76. LinkGoogle Scholar1. HaynesMulrowHuthAltmanGardner RCEDM. More informative abstracts revisited. Ann Intern Med. 1990;113:69-76. LinkGoogle Scholar2. Gotzsche P. Methodology and overt and hidden bias in reports of 196 double-blind trial of nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Controlled Clin Trials. 1989;10:31-56. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Cedars-Sinai Medical Center Los Angeles, CA 90048-0750 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byStructured abstracts: a modest dissent 1 November 1990Volume 113, Issue 9Page: 722-723 Issue Published: 1 November 1990 PDF downloadLoading ...
Rib Lesions—Two of a Kind
Authors: Edward H. Eliscu
Journal: JAMA (1969)

Dr. Raymond A. Berke: This 39-year-old white woman entered the hospital with a history of intermittent sharp pain in her back and side of eight months' duration. The pain was brought on by coughing or twisting and usually was relieved by the patient leaning forward. There was no history of trauma. Review of systems was not remarkable. Physical examination revealed a tender mass over the tenth rib posteriorly. The hematocrit reading was 34% and level of alkaline phosphatase, 7.1 Bodansky units. The results of all other laboratory examinations, including calcium, phosphorus, bilirubin, proteins, and bone marrow studies were normal. Chest roentgenograms were done at the time of admission. <h3>Discussion</h3> Dr. Laurence L. Robbins: Dr. New, can you see a lesion? Dr. Paul F. J. New: Yes, there is quite a large osteolytic lesion in the posterior portion of the left tenth rib with an associated fracture (Fig 1). This is
From the Centers for Disease Control and Prevention. Progress toward global eradication of poliomyelitis, 1988-1993
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Miscellany.
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Ambulatory Care of Patients With Left Ventricular Assist Devices
Authors: Christof Schmid, Dieter Hammel, Mario C. Deng, Michael Weyand, Hideo Baba, Tonny D. T. Tjan, Gabriele Drees, Norbert Roeder, Christoph Schmidt, Hans H. Scheld
Journal: Circulation (1999)

Background —Left ventricular assist devices (LVAD) have revolutionized the treatment of patients with acute and chronic heart failure as they provide a high quality of life. We report on our experience with patients receiving ambulatory care after LVAD implantation. Methods and Results —Since July 1995, 46 patients with a mean age of 45±11 years underwent implantation of an electrically driven LVAD with portable controller and batteries. Sixteen (35%) patients bridged &gt;30 days were treated in part on an outpatient basis. After LVAD implantation, they were treated in the hospital for 86±32 days (range 40 to 153 days). Afterward, they received ambulatory care for 74±76 days (range 2 to 301 days, total experience 1206 days). In 13 cases, the outpatient treatment was interrupted by 1.7±1.7 readmissions, for a total of 32±42 days (median 19 days). Reasons for readmission included systemic or drive line infections (incidence 0.0066 per outpatient day), suspected or true thromboembolic events (incidence 0.0066 per outpatient day), and suspected malfunction of the LVAD. One patient supported as alternative to transplantation died after cerebral bleeding after 244 days, 1 patient with a history of acute myocarditis had ventricular fibrillation during LVAD assist while being at home for 177 days and died in a low output state, 10 patients were given transplantation after a mean support interval of 206±88 days, and 4 patients currently await heart transplantation. Conclusions —Outpatient treatment after LVAD implantation is feasible, and severe complications are uncommon.
Chronic inflammatory bowel disease in childhood
Authors: S K F Chong, J A Walker-Smith
Journal: BMJ (1982)

The diagnosis of Crohn's disease in childhood has been facilitated by the use of fibreoptic endoscopy with biopsies, complemented by double-contrast radiology.Clinical suspicion leads initially to several relevant blood tests.These are followed by endoscopy and multiple colonic biopsies or barium follow-through studies depending on whether large-bowel or small-bowel disease is suspected.The present approach to diagnosis is based on corroborative investigative techniquesendoscopy, radiology, and histology.The availability of paediatric colonoscopes of small diameter should make it possible for paediatricians to perform limited exam- inations, but when more extensive endoscopy is indicated the child should be referred to special centres.
Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05).
Authors: Michiaki Unno, Fuyuhiko Motoi, Yutaka Matsuyama, Sohei Satoi, Ippei Matsumoto, Suefumi Aosasa, Hirofumi Shirakawa, Keita Wada, Tsutomu Fujii, Hideyuki Yoshitomi, Shinichiro Takahashi, Masayuki Sho, Hideki Ueno, Tomoo Kosuge
Journal: Journal of Clinical Oncology (2019)

189 Background: Despite improvements of postoperative adjuvant therapy for resected pancreatic ductal adenocarcinoma (PDAC), its prognosis remains poor. A randomized controlled trial has begun to compare neoadjuvant chemotherapy using gemcitabine and S1 (NAC-GS) with upfront surgery (Up-S) for patients with PDAC planned resection. Methods: Patients were enrolled after the diagnosis of resectable PDAC with histological confirmation. They were randomly assigned as either NAC-GS or Up-S. In NAC-GS, gemcitabine was provided at a dose of 1 g/m 2 on day 1 and 8 and oral S-1 was administered at a dose of 40 mg/m 2 twice daily on 1-14 days. Patients received 2 cycles of this regimen. S-1 adjuvant for 6 months was administered for the patients with curative resection and fully recovered within 10 weeks after surgery in both arms. The primary endpoint for the phase III part was overall survival (OS); secondary endpoints included adverse events, resection rate, recurrence-free survival, residual tumor status, nodal metastases, and tumor marker kinetics. The target sample size required 163 patients (α-error 0.05; power 0.8) in each arm. The trial was conducted by the Health Labor Sciences Research Grant (H22-009) of Japan and registered with the UMIN Clinical Trials Registry as UMIN000009634. Results: From January 2013 to January 2016, 364 patients were enrolled in 57 centers (182 to NAC-GS and 182 to Up-S). Of these, two were excluded because of ineligibility, therefore 182 patients in NAC-GS and 180 in Up-S constituted the ITT analysis-set. The median OS was 36.7 months in NAC-GS and 26.6 months in Up-S; HR 0.72 (95% confidential interval 0.55-0.94; p=0.015 [stratified log-rank test]). Grade 3 or 4 adverse events frequently (72.8%) observed in NAC-GS were leukopenia or neutropenia. However, the resection rate, R0 resection rate, and morbidity of the operation were equivalent in the two groups. There was no perioperative mortality in either group. Conclusions: This phase III study demonstrated the significant survival benefits of NAC-GS treatment. Therefore, the results indicated that neoadjuvant chemotherapy could be a new standard for patients with resectable PDAC. Clinical trial information: UMIN000009634.
Government Services
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pulmonary artery catheterization. Can there be an integrated strategy for guideline development and research promotion?
Authors: C D Naylor, W J Sibbald, C L Sprung, S P Pinfold, J E Calvin, F B Cerra
Journal: JAMA (1993)

To review the evidence regarding indications for pulmonary artery catheterization (PAC) in critically ill patients, and to propose a guideline-generating process that would encourage randomized controlled trials of PAC.Computerized and manual search for randomized trials involving PAC as an integral part of the protocol, published as of October 1992. Manual search for guidelines endorsed by specialty societies and/or proposed by expert panels following an explicit group process.Four trials suggest benefit from PAC for pre- or perioperative management of high-risk surgical patients. Two others indicate that PAC for low-risk aortic aneurysm surgery confers no advantages. Use of PAC to guide therapy aimed at improved mixed venous oxygen saturation was beneficial compared with usual care with PAC in two small trials among patients with septic shock and severe trauma. Other PAC indications are either untested or inadequately tested by small trials. Large trials are needed, but trials to date have been impeded by clinicians' uncertainty about PAC and unwillingness to randomize critically ill patients. No published guidelines for PAC have used a formal group process and/or a hierarchical review of evidence to demarcate proven from unproven indications.We propose a research-promoting expert panel on indications for PAC. Aided by a critical literature review, experts would rate case scenarios on the need for routine PAC with or without a specified intervention strategy. Future trials should test indications where there is either consensus about the uncertainty of need for PAC, or interpanelist disagreement owing to inconclusive evidence. This process could facilitate practice guideline development, utilization management, and large trials of PAC and related interventions.